Rocket Pharma updates progress on RP-A501 for Danon disease

Rocket Pharmaceuticals (RCKT) shares rose 4% after securing a $150M credit facility with Hercules Capital. The funding supports its Phase 2 study of RP-A501 for Danon disease and its cardiovascular pipeline. Early safety data from the first three patients treated under a modified protocol showed no evidence of thrombotic microangiopathy or capillary leak syndrome. The company expects to complete the trial by mid-2027 and report results in mid-2028.

Rocket Pharmaceuticals secured a $150M credit facility from Hercules Capital to support its cardiovascular pipeline, including a Phase 2 study for Danon disease. The facility provides up to $35M initially, with additional funds tied to milestones. Rocket expects current resources to fund operations into Q3 2028, extendable to 2029 with further borrowings.

Rocket Pharmaceuticals (RCKT) presented Phase 2 trial details for its Danon disease gene therapy, RP-A501. The trial aims to enroll 12 male patients, with success criteria including myocardial LAMP2 protein expression and a 10% reduction in left ventricular mass index. Preliminary data showed no immediate safety concerns. The company estimates the U.S. Danon disease population at 10,000-11,000, with a focus on males. Trial completion is expected by mid-2027, with results in mid-2028.

Rocket Pharmaceuticals (RCKT) shared an FDA-aligned plan for its Phase 2 trial of RP-A501 for Danon disease, showing sustained biological activity in Phase 1 follow-up and initial safety data from a modified protocol. The company aims to complete the trial and meet co-primary endpoints for an FDA filing.

Rocket Pharmaceuticals secured a $150m credit facility from Hercules Capital to fund its cardiovascular portfolio, extending its cash runway to Q3 2028. Initial $35m drawn, with additional tranches tied to milestones. Proceeds will advance clinical trials, including RP-A501 for Danon disease. Company had $283.7m in cash as of June 2026.

Rocket Pharmaceuticals (RCKT) updated its Phase II trial for RP-A501, a gene therapy for Danon disease. The company adjusted the protocol after safety events, reducing the dose and removing a C3 inhibitor. The revised regimen showed no severe adverse events in three patients. Rocket aims to enroll 12 patients for the pivotal study, targeting at least seven responders. The company estimates a potential $1B+ peak revenue if approved.